ClinicalTrials.Veeva

Menu

Non-Invasive TMS Neuromodulation for Enduring Balance & Locomotion Restoration in Parkinson's Disease

NYU Langone Health logo

NYU Langone Health

Status

Withdrawn

Conditions

Parkinson's Disease

Treatments

Device: MAGSTIM Rapid2
Device: Transcranial Magnetic Stimulation (TMS)

Study type

Interventional

Funder types

Other

Identifiers

NCT02875041
16-00966

Details and patient eligibility

About

This is a feasibility and exploratory pilot study of adjuvant transcranial magnetic stimulation (TMS) to physical therapy (PT) for locomotion and balance rehabilitation in Parkinson's disease patients.

Full description

The primary outcomes will be feasibility of pairing 10 PT training sessions for PB&G with rTMS therapy immediately following PT treatment session. Secondary outcomes will be exploratory, documenting differential clinical effects of two 'active' rTMS compared to 'sham' rTMS, to investigate ability to improve motor and functional recovery outcomes. Outcome measures will be a combination of assessments regularly conducted during PT treatment sessions validated in people with PD (these will doubly serve as our study measures) and several PD oriented outcomes.

Sex

All

Ages

35 to 89 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of PD confirmed by a neurologist with expertise in movement disorders;
  • Hoehn and Yahr stage 2 to 4;
  • On L-Dopa and/or Dopamine Agonist daily treatment regimen;
  • On a stable medication regimen since at least 2 weeks prior the enrolment in the study and, in the view of the treating neurologist, unlikely to require medication adjustments in the following 3 months;
  • Posture, locomotion and balance deficits requiring at least 10 sessions of PT.

Exclusion criteria

  • History of seizure disorder, including febrile seizures, fainting spells or syncope of unknown cause(s);
  • Neurological disorder other than PD including stroke (mild-to-moderate micro vascular disease is allowed), traumatic brain injury, brain tumors, hydrocephalus;
  • Major or unstable medical illness;
  • Pacemakers, neurostimulators, tattoos or metal foreign bodies in the head area (dental fillings are allowed);
  • Untreated depression; or Beck Depression Inventory (BDI)>22
  • Taking any of the following medications within the four weeks prior to the start of the study: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, bupropion, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, and theophylline;
  • History of moderate or severe dementia, or history of Mini Mental State Examination (MMSE) <20 or Montreal Cognitive Assessment (MoCA) <22;
  • Physical therapy treatment contraindications as determined by physiotherapist.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

0 participants in 2 patient groups

Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy
Experimental group
Description:
TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
Treatment:
Device: Transcranial Magnetic Stimulation (TMS)
MAGSTIM Rapid2 Therapy System
Active Comparator group
Description:
MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
Treatment:
Device: MAGSTIM Rapid2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems